Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics is set to present at the 2024 ASCO Annual Meeting, showcasing new data from their ABILITY-1 Study on MDNA11, an innovative immunotherapy for solid tumors, and comparing survival outcomes of bizaxofusp against a control arm for recurrent glioblastoma. Their presentations will highlight MDNA11’s potential in monotherapy and in combination with pembrolizumab, and bizaxofusp’s performance in Phase 2 trials for a lethal brain cancer.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
